TNF and COVID-19: Strikingly, significant positive and negative associations with positivity in the serological tests, respectively, were found between the use of mesalazine (p = 0.019) and monoclonal antibodies (Figure 1, p = 0.005, p = 0.074 for anti-TNF drugs, not significant for other biologics alone), but not with the severity of COVID-19 symptoms (p = 0.153 and 0.671).